Cadila Healthcare along with its arm Zydus Pharmaceuticals (USA) Inc has reached settlement of patent litigation with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, for Revlimid (lenalidomide). As part of the settlement, the parties will file consent judgments with the United States District Court for the District of New Jersey that enjoin Zydus Cadila from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
